GlobeNewswire

IRIDEOS Acquires Enter

Dela

IRIDEOS Enhances Recent Strategic Acquisitions With Purchase of Leading Italian-Based Network and Cloud Services Provider

MILAN, Italy, June 18, 2018 (GLOBE NEWSWIRE) -- IRIDEOS, the new Italian ICT provider for Businesses and Public Administration, announces today the acquisition of Enter, a leader in network and cloud services based in Italy. This purchase is the most recent of IRIDEOS acquisitions as the company works to consolidate the cloud and data center market throughout Italy.

"With this new acquisition, our growth path continues, focused on strengthening our assets and skills in the Italian ICT space," says  Mauro  Maia, CEO of IRIDEOS. "A wider portfolio of services is now available for our customers, with new cloud solutions and international connectivity."

As a leading ISP focused on providing global network connectivity, Enter's IP backbone spans 35+ Points of Presence (PoPs) worldwide, providing a wide range of network services, including Ethernet, VPN and cloud interconnection. Enter also provides Cloud Infrastructure-as-a-Service (IaaS) solutions, the first European, OpenStack-based service of its kind. This comprehensive solution provides customers with the computing, storage, network, DNS and CDN solutions they require to build an effective cloud solution.

"This is an exciting time for the Italian telecommunications industry as IRIDEOS works to consolidate cloud, network and data center providers throughout the region," shares Ivan Botta, CEO, Enter. "We look forward to joining IRIDEOS as we work together to provide solutions that exceed customer expectations."

As a result of this strategic acquisition, Enter will be part of a wider portfolio of services with a densified fiber footprint and additional colocation opportunities throughout the Italian market and will continue to deliver high-quality cloud and connectivity solutions to users around the globe.

IRIDEOS' purchase of Enter follows the recent acquisitions of Infracom Italia, KPNQwest Italia, MC-link and BiG TLC. As a result of these purchases, the IRIDEOS technological platform now integrates 12 data centers across Milan, Rome, Trento, and Verona, the largest Italian private Internet exchange (Avalon) and 15,000 km of proprietary optical fiber along the major highways.

For more information about IRIDEOS, visit www.irideos.it/en/. To learn more about Enter, visit www.enter.it/en/

About IRIDEOS

IRIDEOS is the new Italian ICT provider for Businesses and Public Administration. 80% owned by F2i SGR and 20% by the European fund Marguerite, IRIDEOS aggregates and consolidates the assets and skills of four Italian operators focused on business customers: Infracom, KPNQWest Italia, MC-link and BiG TLC. IRIDEOS' solutions combine cloud, data center, optical fiber, security and managed services, leveraging a technological platform that integrates 10 data centers in Milan, Rome, Trento and Verona, the largest Italian private Internet exchange (Avalon) and a fiber-optic network of over 15,000 km along the major highways.

About Enter

Enter is a leading European network and cloud provider focused on providing connectivity, data center and internet solutions throughout Europe, the U.S. and Asia-Pacific. The company's IP backbone spans Europe's largest PoPs (Frankfurt, Amsterdam, London, Paris, Madrid, Stockholm, Brussels, Vienna, Prague and Budapest), as well as the U.S. (New York) and Far East (Hong Kong).

In 2012, the company developed Enter Cloud Suite, the first European, OpenStack- based cloud IaaS service available in Milan, Frankfurt and Amsterdam, and is one of the official cloud platforms of 52 European institutions and agencies, such as the European Parliament and Court of Justice.

MEDIA CONTACT:

Giuseppe Sammartino
External Relations IRIDEOS S.p.A. Mobile +39 335.3000.24
gsam.ext@irideos.it www.irideos.it

iMiller Public Relations for Enter
+1.866.307.2510
media@ente.eu




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IRIDEOS via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum